Kwon HY, Kim H, Godman B. Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications. Front Pharmacol. 2018;9:938. https://doi.org/10.3389/fphar.2018.00938 PMID:30233363 DOI: https://doi.org/10.3389/fphar.2018.00938

Oye KA, Eichler HG, Hoos A, Mori Y, Mullin TM, Pearson M. Pharmaceutical licensing and reimbursement in the European Union, United States, and Japan. Clin Pharmacol Ther. 2016;100(6):626-632. https://doi.org/10.1002/cpt.505 PMID:27618128 DOI: https://doi.org/10.1002/cpt.505

Zamora B, Maignen F, O’Neill P, Mestre-Ferrandiz J, Garau M. Comparing access to orphan medicinal products in Europe. Orphanet J Rare Dis. 2019;14(1):95. https://doi.org/10.1186/s13023-019-1078-5 PMID:31053154 DOI: https://doi.org/10.1186/s13023-019-1078-5

EFPIA Patients W.A.I.T. Indicator 2021 Survey. July 2022. Online https://www.efpia.eu/media/676539/efpia-patient-wait-indicator_update-july-2022_final.pdf (Accessed March 2023).

Gallo V, Alessi E, Montilla S, Altamura G, Traversa G, Trotta F. The timelines for the price and reimbursement authorization in Italy 2018-2020. Front Med (Lausanne). 2022;9:1055359. https://doi.org/10.3389/fmed.2022.1055359 PMID:36619645 DOI: https://doi.org/10.3389/fmed.2022.1055359

Strategia A, ed. Economia del Farmaco Settore Hta ed Economia Del Farmaco, Rapporto sulle tempistiche delle procedure di prezzo e rimborso dei farmaci nel quadriennio 2018-2022. Aprile 2022 - Online https://www.aifa.gov.it/documents/20142/1807239/2023.04.27_Rapporto_procedure_prezzi_rimborso_farmaci_2018-2022.pdf (accessed May 2022).

Farmaco ASEFSHEd. Rapporto sulle tempistiche delle procedure di prezzo e rimborso dei farmaci nel quadriennio 2018-2020. Settembre 2021. Online https://www.aifa.gov.it/documents/20142/1307543/2021.09.06_Rapporto_procedure_prezzi_rimborso_farmaci_triennio_2018-2020.PDF (Accessed March 2023)

Russo P, Mennini FS, Siviero PD, Rasi G. Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers. Ann Oncol. 2010;21(10):2081-2087. https://doi.org/10.1093/annonc/mdq097 PMID:20335370 DOI: https://doi.org/10.1093/annonc/mdq097

Raimondo P, Casilli G, Isernia M, et al. [Not Available]. Glob Reg Health Technol Assess. 2020;7:109-114. https://doi.org/10.33393/grhta.2020.2173 PMID:36627956 DOI: https://doi.org/10.33393/grhta.2020.2173

Canonico, P.L., et al. Rare Disease Deep Dive & Proposals (EXPLORARE). Febbraio 2023. Online: https://www.isporitaly.org/index.php/progetti/item/download/182_96d5ae15fd01d3896151e8a0cf0cc257 (Accessed March 2023).

AIFA. Decreto 2 agosto 2019. Criteri e modalita’ con cui l’Agenzia italiana del farmaco determina, mediante negoziazione, i prezzi dei farmaci rimborsati dal Servizio sanitario nazionale (20A03810) (GU Serie Generale n.185 del 24-07-2020), p.6. Online http://www.salute.gov.it/imgs/C_17_notizie_3848_listaFile_itemName_0_file.pdf (Accessed February 2023).

Orphanet Report Series. Lists of medicinal products for rare diseases in Europe. Online: https://www.orpha.net/orphacom/cahiers/docs/GB/list_of_orphan_drugs_in_europe.pdf (Accessed March 2023).

European Medicines Agency (EMA). Official website of the European Union. Human Medicines search. Online: https://www.ema.europa.eu/en/medicines (Accessed March 2023).

Gazzetta ufficiale della Repubblica Italiana. Online: https://www.gazzettaufficiale.it/ricerca/atto/serie_generale/originario?reset=true&normativi=false (Accessed March 2023).

Agenzia Italiana del Farmaco (AIFA). Lista Farmaci Innovativi. Online: https://www.aifa.gov.it/farmaci-innovativi (Accessed March 2023).

Gazzetta ufficiale dell'Unione europea. EUR-Lex Aaccesso al diritto dell'Unione Europea. Online: https://eur-lex.europa.eu/oj/direct-access.html?locale=it (Accessed March 2023).

Agenzia Italiana del Farmaco (AIFA). Esiti delle riunioni CTS e CPR. Online https://www.aifa.gov.it/ricerca?q=esiti+cts (Accessed March 2023).

Osservatorio Farmaci Orfani (OSSFOR). VI Rapporto Annuale: Investimenti e trasparenza dei processi: le condizioni per garantire l’equità di accesso ai malati rari. 2022. Online: http://www.osservatoriofarmaciorfani.it/wp-content/uploads/2023/01/VI_Rapporto_OSSFOR_Web.pdf (Accessed July 2023).

Cox GF. The art and science of choosing efficacy endpoints for rare disease clinical trials. Am J Med Genet A. 2018;176(4):759-772. https://doi.org/10.1002/ajmg.a.38629 PMID:29423972 DOI: https://doi.org/10.1002/ajmg.a.38629